POSA125 Comparing Healthcare Cost Among Empagliflozin, DPP-4 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A German Claims Data Analysis
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.268
https://www.valueinhealthjournal.com/article/S1098-3015(21)02063-5/fulltext
Section Title :
Section Order :
11041
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02063-5&doi=10.1016/j.jval.2021.11.268